Specs Compound Handling BV (Specs) announced that eMolecules made a bid to acquire 100% of the company’s shares. The shareholders of Specs – a trader in medical compounds for research – decided to accept this offer of €11 per share in cash. The last known number of issued shares is 1.7 million, bringing the take-over sum to €18.7 million. This take-over also includes the purchase of the depository receipts (DRs) of Specs shares on the NPEX exchange. The bid implies a premium of 18% on the last share price of €9.30 or 10% on Specs’s listing price of €10.
As part of the acquisition, the undisclosed buyer acquires all shares of Specs, and Specs withdraws the associated DRs. The last trading day for Specs Compound Handling was on Tuesday, May 23, 2023. “The activities of both companies are complementary. The acquisition aligns well with Specs’ growth plans presented during the NPEX listing”, according to Johan Tijhuis, CEO of Specs.
NPEX is a portfolio company of Icecat Capital since last month, which helps SME business to raise growth capital from retail and professional investors.
Disclaimer: This news post is for informational purposes only. It should not be considered as financial advice or a recommendation to buy or sell securities. Readers are encouraged to conduct their own research and consult with a financial advisor before making any investment decisions.
Chinese e-commerce platforms have become a mainstream part of online shopping in Europe, but their…
Upload your document via HTTP/FTP For regular updates to work, this option must be chosen:…
Walmart’s latest results have raised questions about the strength of the U.S. consumer. However, behind…
Release 257 brings more flexibility to content delivery while continuing Icecat’s work on platform reliability…
Robots played music, boxed, mixed drinks, directed traffic, and demonstrated increasingly human-like movements at this…
Artificial intelligence is rapidly becoming part of everyday life, but enthusiasm is not necessarily growing…